New Collaboration Builds On Recent Malaria Antigen Discovery
In a bid to further diversify the range of options available to malaria vaccine scientists, the PATH Malaria Vaccine Initiative (MVI) and the Seattle Biomedical Research Institute (SBRI) today announced a collaboration that will place previously unused parts of the malaria parasite in the hands of vaccine developers.
More: continued here
Filed under: Tropical on March 13th, 2009
You must be logged in to post a comment.